RAPP

insider transactions

Rapport Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-965.5K

0 buy · 965.5K sell

Net value · 365d

-$37.9M

$0 in · $37.9M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 965.5K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 10, 26

Paul M Silva

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Wendy B. Young

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Ramiro Sanchez

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Robert J Perez

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Steven M Paul

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

John Maraganore

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Reid M Huber

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

James Healy

Director

$0

15.2K sh

Own New
Sell·S
May 26, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$743.8K

18.6K sh · $40.05

Own -0%
Sell·S
May 11, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$5.4M

133.6K sh · $40.24

Own -2%
Sell·S
May 8, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$202.3K

5.0K sh · $40.31

Own -0%
Sell·S
May 7, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$10.9M

271.5K sh · $40.12

Own -4%
Exercise·C
May 4, 26

Steven M Paul

Director

$0

210.5K sh

Own New
Exercise·C
May 4, 26

Steven M Paul

Director

—

67.0K sh

Own +8%
Exercise·C
May 4, 26

James Healy

Director

$0

2.5M sh

Own New
Exercise·C
May 4, 26

James Healy

Director

$0

6.1M sh

Own New
Exercise·C
May 4, 26

James Healy

Director

—

804.4K sh

Own +42%
Exercise·C
May 4, 26

James Healy

Director

—

1.9M sh

Own New
Grant·A
Apr 30, 26

Steven M Paul

Director

$0

991.2K sh

Own New
Grant·A
Apr 30, 26

Steven M Paul

Director

$0

12.3K sh

Own New
Sell·S
Apr 17, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$17.2M

426.0K sh · $40.32

Own -6%
Sell·S
Apr 17, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$808.8K

20.2K sh · $39.99

Own -8%
Sell·S
Apr 14, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$357.8K

10.2K sh · $35.08

Own -4%
Sell·S
Apr 13, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$320.5K

9.2K sh · $34.97

Own -3%
Sell·S
Apr 10, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$17.5K

500 sh · $34.98

Own -0%
Sell·S
Apr 8, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$12.6K

360 sh · $34.90

Own -0%
Sell·S
Mar 30, 26

Cheryl Gault

Chief Operating Officer · 10b5-1

$81.1K

2.8K sh · $28.55

Own -2%
Sell·S
Mar 30, 26

Cheryl Gault

Chief Operating Officer · 10b5-1

$200.8K

7.2K sh · $28.04

Own -4%
Sell·S
Mar 25, 26

Krishnaswamy Yeleswaram

Chief Development Officer · 10b5-1

$303.4K

10.1K sh · $29.99

Own -3%
Sell·S
Mar 5, 26

Cheryl Gault

Chief Operating Officer

$58.3K

2.0K sh · $28.93

Own -1%
Exercise·M
Feb 19, 26

David Bredt

Chief Scientific Officer · 10b5-1

$0

6.0K sh

Own +7%
Exercise·M
Feb 19, 26

David Bredt

Chief Scientific Officer · 10b5-1

$10.8K

6.0K sh · $1.80

Own +2%
Sell·S
Feb 18, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$62.6K

2.1K sh · $29.80

Own -9%
Sell·S
Feb 18, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$86.6K

3.0K sh · $29.04

Own -12%
Sell·S
Feb 18, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$68.0K

2.3K sh · $29.80

Own -0%
Sell·S
Feb 18, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$103.2K

3.6K sh · $29.05

Own -1%
Sell·S
Feb 17, 26

David Bredt

Chief Scientific Officer · 10b5-1

$65.1K

2.2K sh · $29.59

Own -1%
Sell·S
Feb 17, 26

David Bredt

Chief Scientific Officer · 10b5-1

$156.3K

5.4K sh · $28.95

Own -1%
Sell·S
Feb 17, 26

David Bredt

Chief Scientific Officer · 10b5-1

$25.2K

900 sh · $28.02

Own -0%
Grant·A
Feb 2, 26

Jeffrey Sevigny

Chief Medical Officer

$0

130.0K sh

Own New
Grant·A
Feb 2, 26

Krishnaswamy Yeleswaram

Chief Development Officer

$0

120.0K sh

Own New
Grant·A
Feb 2, 26

Troy A. Ignelzi KEY

Chief Financial Officer

$0

148.0K sh

Own New
Grant·A
Feb 2, 26

Cheryl Gault

Chief Operating Officer

$0

132.0K sh

Own New
Grant·A
Feb 2, 26

Abraham Ceesay KEY

Chief Executive Officer

$0

428.0K sh

Own New
Grant·A
Feb 2, 26

David Bredt

Chief Scientific Officer

$0

103.0K sh

Own New
Sell·S
Jan 20, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$132.7K

5.1K sh · $26.11

Own -16%
Sell·S
Jan 20, 26

Abraham Ceesay KEY

Chief Executive Officer · 10b5-1

$152.3K

5.8K sh · $26.12

Own -1%
Sell·S
Jan 15, 26

David Bredt

Chief Scientific Officer · 10b5-1

$5.5K

200 sh · $27.40

Own -0%
Sell·S
Jan 15, 26

David Bredt

Chief Scientific Officer · 10b5-1

$222.7K

8.3K sh · $26.83

Own -2%
Sell·S
Dec 31, 25

Krishnaswamy Yeleswaram

Chief Development Officer

$85.3K

2.8K sh · $30.05

Own -1%
Grant·A
Dec 31, 25

Krishnaswamy Yeleswaram

Chief Development Officer

—

9.0K sh

Own +3%
Sell·S
Dec 31, 25

David Bredt

Chief Scientific Officer

$197.3K

6.6K sh · $30.05

Own -2%
Grant·A
Dec 31, 25

David Bredt

Chief Scientific Officer

—

18.0K sh

Own +5%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 10, 2026	Paul M Silva	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Wendy B. Young	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Ramiro Sanchez	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Robert J Perez	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Steven M Paul	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	John Maraganore	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Reid M Huber	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	James Healy	Director	Grant A	15.2K	New	—	$0
May 26, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	18.6K	-0%	$40.05	$743.8K
May 11, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	133.6K	-2%	$40.24	$5.4M
May 8, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	5.0K	-0%	$40.31	$202.3K
May 7, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	271.5K	-4%	$40.12	$10.9M
May 4, 2026	Steven M Paul	Director	Exercise C	210.5K	New	—	$0
May 4, 2026	Steven M Paul	Director	Exercise C	67.0K	+8%	—	—
May 4, 2026	James Healy	Director	Exercise C	2.5M	New	—	$0
May 4, 2026	James Healy	Director	Exercise C	6.1M	New	—	$0
May 4, 2026	James Healy	Director	Exercise C	804.4K	+42%	—	—
May 4, 2026	James Healy	Director	Exercise C	1.9M	New	—	—
Apr 30, 2026	Steven M Paul	Director	Grant A	991.2K	New	—	$0
Apr 30, 2026	Steven M Paul	Director	Grant A	12.3K	New	—	$0
Apr 17, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	426.0K	-6%	$40.32	$17.2M
Apr 17, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	20.2K	-8%	$39.99	$808.8K
Apr 14, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	10.2K	-4%	$35.08	$357.8K
Apr 13, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	9.2K	-3%	$34.97	$320.5K
Apr 10, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	500	-0%	$34.98	$17.5K
Apr 8, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	360	-0%	$34.90	$12.6K
Mar 30, 2026	Cheryl Gault 10b5-1	Chief Operating Officer	Sell S	2.8K	-2%	$28.55	$81.1K
Mar 30, 2026	Cheryl Gault 10b5-1	Chief Operating Officer	Sell S	7.2K	-4%	$28.04	$200.8K
Mar 25, 2026	Krishnaswamy Yeleswaram 10b5-1	Chief Development Officer	Sell S	10.1K	-3%	$29.99	$303.4K
Mar 5, 2026	Cheryl Gault	Chief Operating Officer	Sell S	2.0K	-1%	$28.93	$58.3K
Feb 19, 2026	David Bredt 10b5-1	Chief Scientific Officer	Exercise M	6.0K	+7%	—	$0
Feb 19, 2026	David Bredt 10b5-1	Chief Scientific Officer	Exercise M	6.0K	+2%	$1.80	$10.8K
Feb 18, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	2.1K	-9%	$29.80	$62.6K
Feb 18, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	3.0K	-12%	$29.04	$86.6K
Feb 18, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	2.3K	-0%	$29.80	$68.0K
Feb 18, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	3.6K	-1%	$29.05	$103.2K
Feb 17, 2026	David Bredt 10b5-1	Chief Scientific Officer	Sell S	2.2K	-1%	$29.59	$65.1K
Feb 17, 2026	David Bredt 10b5-1	Chief Scientific Officer	Sell S	5.4K	-1%	$28.95	$156.3K
Feb 17, 2026	David Bredt 10b5-1	Chief Scientific Officer	Sell S	900	-0%	$28.02	$25.2K
Feb 2, 2026	Jeffrey Sevigny	Chief Medical Officer	Grant A	130.0K	New	—	$0
Feb 2, 2026	Krishnaswamy Yeleswaram	Chief Development Officer	Grant A	120.0K	New	—	$0
Feb 2, 2026	Troy A. Ignelzi KEY	Chief Financial Officer	Grant A	148.0K	New	—	$0
Feb 2, 2026	Cheryl Gault	Chief Operating Officer	Grant A	132.0K	New	—	$0
Feb 2, 2026	Abraham Ceesay KEY	Chief Executive Officer	Grant A	428.0K	New	—	$0
Feb 2, 2026	David Bredt	Chief Scientific Officer	Grant A	103.0K	New	—	$0
Jan 20, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	5.1K	-16%	$26.11	$132.7K
Jan 20, 2026	Abraham Ceesay KEY 10b5-1	Chief Executive Officer	Sell S	5.8K	-1%	$26.12	$152.3K
Jan 15, 2026	David Bredt 10b5-1	Chief Scientific Officer	Sell S	200	-0%	$27.40	$5.5K
Jan 15, 2026	David Bredt 10b5-1	Chief Scientific Officer	Sell S	8.3K	-2%	$26.83	$222.7K
Dec 31, 2025	Krishnaswamy Yeleswaram	Chief Development Officer	Sell S	2.8K	-1%	$30.05	$85.3K
Dec 31, 2025	Krishnaswamy Yeleswaram	Chief Development Officer	Grant A	9.0K	+3%	—	—
Dec 31, 2025	David Bredt	Chief Scientific Officer	Sell S	6.6K	-2%	$30.05	$197.3K
Dec 31, 2025	David Bredt	Chief Scientific Officer	Grant A	18.0K	+5%	—	—

About RAPP insider trading

This page tracks insider transactions for Rapport Therapeutics, Inc. (RAPP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.